Complement Therapeutics is a spin-out from The University of Manchester that focuses on developing treatments for Complement-related diseases, particularly age-related macular degeneration. The company conducts translational research to gain insights into the Complement System and its dysregulation in macular degeneration.

Complement Therapeutics

Seroba Lifesciences is a European life sciences venture capital firm focused on value creation through backing innovations in biotech and medtech.

Seroba Lifesciences

Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.

Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.

The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

BioGeneration Ventures

Forbion Capital Partners

Panakes Partners

Seroba Life Sciences

Gimv

Hadean Ventures

Cambridge Innovation Capital

Wow! Our team was featured on the big screen in Times Square NYC! Thanks Nasdaq for celebrating this milestone with us! 🎉
 
Even Mo'Nique (Netflix) put on a big smile when she saw the announcement.

#nasdaq #SeriesA #funding #biotech #timesquare #nyc #team

🌟 Exciting News! 🌟
 
The June Edition of BioProcess International has published a new article featuring Pamela Whalley, Associate Director CMC, on the topic  presented at Advanced Therapies in Miami, earlier this year: Partnering for Gene Therapy Manufacturing - What is the Key to Success?
 
In this insightful piece, Pam explores the crucial factors that gene therapy developers must consider when selecting a CDMO (Contract Development and Manufacturing Organization) and highlights the importance of demanding a pilot study to ensure success.
 
Read the full article here: https://lnkd.in/gynu-mnA
 
#GeneTherapy #Biotech #CDMO #Pharmaceuticals #BioProcess #ManufacturingSuccess #HealthcareInnovation #BPI #CMC #complement #conference

Excited to be on the panel today to discuss CMC Best Practices at Oxford Global Gene Therapy Development2024 conference.

OxfordGlobal Conferences UK 
Complement Therapeutics

The Cell and Gene Therapy Catapult (CGT Catapult), Touchlight, and Complement Therapeutics, today announce that they have been awarded over £1 million in a grant from Innovate UK.

During this two-year project, Touchlight, the CGT Catapult and Complement Therapeutics will combine their expertise in #GeneTherapy development and manufacturing to develop an innovative recombinant adeno-associated virus (rAAV) production process.

Learn more: https://buff.ly/4b9xzYL 

#AdvancedTherapies #ATMPs #Manufacturing #Innovation

📣 It’s #conference season! Our Director of Biomarker and Bioanalysis, Rachel Green will be a guest speaker at this year’s Workshops on Recent Issues in Bioanalysis conference in Texas, USA. Rachel will be presenting on our novel complement precision medicine platform (CPM) on May 9th, so don’t miss out!
 
Find the event’s agenda here: https://lnkd.in/gzvSY7HQ
 
#WRIB #WRIB2024 #research #ophthalmologyresearch #guestspeaker #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #texas #nonclinical #bioanalysis #biomarker #novel #platform

📣 Exciting news! The non-clinical data from our lead asset, CTx001, has been approved for showcasing in a poster format at this year's American Society of Gene & Cell Therapy (ASGCT) on May 10th.
 
Our CTO, Matthias Hebben and VP Operations, Mustafa Munye will be attending the conference, so don't miss the opportunity to speak with them! 
 
#asgct #asgct2024 #research #ophthalmologyresearch #posterpresentation #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #baltimore #nonclinical

📣 With the American Society of Gene & Cell Therapy (ASGCT) approaching on May 7-11th, don’t miss out on our CTO, Matthias Hebben discussing AAV manufacturing platforms to successfully support clinical development at 10:20 AM in Ballroom 3.  
 
Find the event’s agenda here: https://lnkd.in/gSjPsVn

#asgct #asgct2024 #research #ophthalmologyresearch #aav #manufacturing #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #baltimore #nonclinical #cmc #AAVmanufacturing #conferences #guestspeaker

📢 The non-clinical data from our lead programme, CTx001, has been accepted for a poster presentation at Association for Research in Vision and Ophthalmology (ARVO) 2024. 

Our team, including Rafiq Hasan, Dennis Keefe, and parisa zamiri will be attending, so make sure to drop them a message! 
 
#arvo #arvo2024 #research #ophthalmologyresearch #posterpresentation #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #seattle #nonclinical

🌟  The full Complement team had an absolute blast at our recent team building day at the TEWIN BURY FARM LIMITED!
 
We kicked off the day with a diversity of thought workshop 📒 where we had the chance to explore each other's backgrounds, experiences, and perspectives. This session proved to be invaluable, fostering understanding, empathy, and unity within our team 🤝.
 
We also engaged in thrilling activities designed to test our skills and strengthen teamwork. Axe throwing 🎯 brought out our competitive spirits, while archery 🏹 and laser clay shooting 🎇 put our precision and focus to the test.

Happy (early) Easter 🐣 from Complement Therapeutics !

#TeamBuilding #DiversityandInclusion #happyeaster #ComplementTherapeutics #teambonding #easter #team #complement

We are excited to welcome Kathryn Parsley, MPhil, Ph.D, to our team as Vice President, Regulatory Affairs! 🎊

Kathryn holds an MPhil in Microbiology/Immunology and a PhD in Molecular Immunology/gene therapy. She began her career in anthrax vaccine research at CAMR, UK, then spent 12 years at the Institute of Child Health and Great Ormond Street Hospital NHS Trust, UK, managing gene and cell-based Phase I/II clinical trials. She transitioned to PPD as a Senior Regulatory Affairs Manager, specializing in global Phase I-IV studies, gene therapy, and GMO products. Kathryn later joined Boyd Consultants and Gyroscope Therapeutics before moving to Novartis. She also contributes to ATMP education and recently co-authored an article on EU Clinical Trials Regulation and European GMO legislation for TOPRA Regulatory Rapporteur.

#WelcomeAboard #GeneTherapy #ophthalmology #ComplementBiology #team #JobOpening #JoinUs

Metric
Company Name	Complement Therapeutics	Seroba Lifesciences
Symbol
MSH ID	COM:COMPLEMENTTX	COM:SEROBA-LIFESCIENCES
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance
Industry	Biotechnology	Venture Capital
Country	GB	IE
Stage
Employee Count
Website	complementtx.com	seroba-lifesciences.com
LinkedIn	complement-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		606
Web Traffic Growth		-0.87
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COMP

COM:COMPLEMENTTX

Complement Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue